Immatics (IMTX) Non-Current Deferred Tax Liability (2022 - 2026)
Immatics (IMTX) posted Non-Current Deferred Tax Liability of $4.4 million for Q4 2025, up 3.06% sequentially from $4.3 million in Q3 2025, and down 28.55% YoY from $6.2 million in Q4 2024.
Analysis
Immatics (IMTX) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Immatics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $4.4 million in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 28.55% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.4 million (down 28.55% YoY) and the FY2025 annual result came in at $4.3 million, down 31.53% from the prior year.
- Non-Current Deferred Tax Liability advanced to $4.4 million in Q4 2025 per IMTX's latest filing, from $4.3 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $10.0 million in Q4 2022 and troughed at $3.7 million in Q3 2024.
- A 4-year average of $6.0 million and a median of $5.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 16.59% in 2025, down 39.56% in 2025.
- Over 4 years, Non-Current Deferred Tax Liability stood at $10.0 million in 2022, then fell by 19.75% to $8.0 million in 2023, then slipped by 22.79% to $6.2 million in 2024, then slipped by 28.55% to $4.4 million in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $4.4 million, $4.3 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.17 Mn |
| Mar 31, 2026 | 4.52 Mn |
| Dec 31, 2025 | 4.43 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 7.13 Mn |
| Mar 31, 2024 | 7.23 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Dec 31, 2022 | 10.01 Mn |